What we’re seeing in the evidence.
Landscape reads and research notes from the Mindgram team.
Mindgram’s Smart Grid: Built for Biopharma Stakeholders Who Need Answers—Fast
Mindgram’s Smart Grid is a purpose-built platform for biotech and pharma professionals who need to synthesize massive volumes of healthcare data quickly and credibly, move fast, and validate every claim.
How Investors Are Embracing AI for Biotech Conference Planning with Mindgram
Investors can ask Mindgram a natural language question and Mindgram scans information from all leading scientific conferences to source the answer. Mindgram’s AI filtering accelerates the search and analysis process, allowing investors to stay ahead of cutting-edge research and create detailed plans for their teams ahead of each conference.
3 Reasons Healthcare Investors are Using Mindgram to power their biopharma analysis
Mindgram enables investors to pinpoint potential market winners in record time. Using advanced AI algorithms, Mindgram analyzes clinical trial data, market trends, epidemiology, and competitive landscape to answer your natural language queries, synthesizing the best pieces of information into a coherent, cited answer that matches the question. It’s like having a team of experts at your fingertips 24/7. Get faster go vs no-go decisions on investment decisions. Save hundreds of hours searching and extracting insights from conference abstracts. Obtain information from the most relevant sources and compare data across different source types.
How Investors Are Leveraging Mindgram for Smarter Research and Portfolio Management
Tracking developments across news, scientific publications, patents, FDA events, earnings, and financial documents can be overwhelming. Mindgram automates this process, providing a comprehensive view of relevant data. Its Watchlist and AI-powered Summary Digest feature summarizes information around drugs, companies, and/or indications into professional-grade reports, easily shared with internal teams, and can be filtered to certain time periods.
Visualizing the Biotech Landscape: Launching Mindgram Clinical Edge
We are at a unique moment in history where the speed of new innovation and breakthrough discoveries in biotech is accelerating in a non-linear fashion. In 2021, biotech companies raised north of $60 billion from investors and equity markets, marking the year as the biggest of all time.
Introducing Mindgram
Wall Street has traditionally relied on human analysts and reporters to map political and regulatory risks emanating from Washington. From my own experience as an analyst, it is clear to me that traditional models of Washington-driven investment research are outdated, constrained in their scope, and only solve a fraction of the overall research problem.
Nothing filed under that heading yet.